I have commented about this French trial and the principal investigator's approach several weeks ago when it first came out, and as most of you know, I had serious reservations about it. However, I am providing other perspectives which have recently been published. Let's hope the larger trials resolve the question of efficacy with some specifics instead of hype.
#1 The April 3, 2020, notice, from the International Journal of Antimicrobial Agents, states that the March 20 article, "Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non-randomized clinical trial
"does not meet the [International Society of Antimicrobial Chemotherapy's] expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety."
#2 "Elisabeth Bik took a close look at the IJAA article and detailed a long list of serious problems with the study, including questions about its ethical underpinnings, messy confounding variables, missing patients, rushed and conflicted peer review, and confusing data.
#3 Benjamin Davido, MD, an infectious disease specialist at Raymond-Poincaré Hospital in Garches, Paris, states ― "ironically, these 80 patients [in the latest results, presented March 27] could be among the 80% who had a form similar to nasopharyngitis and resolved.
In this illness, we know that there are 80% spontaneous recoveries and 20% so-called severe forms. Therefore, with 80 patients, we are very underpowered. The cohort is too small for a disease in which 80% of the evolution is benign."
#4 "I also wonder about the lack of studies of cohorts where, in retrospect, we could have followed people previously treated with hydroxychloroquine for chronic diseases (eg, rheumatoid arthritis, lupus, etc). Or we could identify all those patients on the health insurance system who had prescriptions."
#5 "It would nevertheless be a shame to think we had found the fountain of youth and realize, in 4 weeks, that we have the same number of deaths. That is the problem. "